Skip to main content

Market Overview

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Share:
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Barclays analyst Gena Wang initiated coverage on Cytokinetics, Incorporated (NASDAQ:CYTK) with an Overweight rating and announced a price target of $5. Cytokinetics shares closed at $38.00 on Wednesday. See how other analysts view this stock.
  • Lake Street analyst Jacob Stephan initiated coverage on ACCESS Newswire Inc. (AMEX:ACCS) with a Buy rating and announced a price target of $15. ACCESS Newswire shares closed at $8.65 on Wednesday. See how other analysts view this stock.

Considering buying CYTK stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

Latest Ratings for CYTK

DateFirmActionFromTo
Dec 2021OppenheimerInitiates Coverage OnOutperform
Dec 2021HC Wainwright & Co.MaintainsBuy
Dec 2021JP MorganInitiates Coverage OnOverweight

View More Analyst Ratings for CYTK

View the Latest Analyst Ratings

 

Related Articles (CYTK + ACCS)

View Comments and Join the Discussion!

Posted-In: Top InitiationsNews Initiation Markets Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com